NCT04261621 (SepSIGN) is a clinical trial in Infection, sponsored by BioMérieux.

Who is sponsoring NCT04261621?

NCT04261621 is sponsored by BioMérieux.

What condition does NCT04261621 study?

NCT04261621 studies Infection, Sepsis.

Is NCT04261621 still recruiting?

NCT04261621 is currently completed. Last updated 1 June 2023.

Last reviewed 2023-06-01 · How we verify

NCT04261621: SepSIGN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Identification of SEPsis SIGNs in Emergency Department

Completed Last updated 1 June 2023

What this trial tests

trial in Infection in 815 participants. Completed in 2 May 2022.

Timeline

6 July 2020

Primary endpoint
2 May 2022

2 May 2022

Quick facts

Lead sponsor	BioMérieux
Status	Completed
Study type	OBSERVATIONAL
Enrollment	815
Start date	6 July 2020
Primary completion	2 May 2022
Estimated completion	2 May 2022
Sites	12 locations across France, United States, Monaco

Conditions studied

Infection — all drugs for Infection →
Sepsis — all drugs for Sepsis →

Sponsor

BioMérieux — full company profile →

Who can join

18 and older, any sex, with Infection or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective of SepSIGN project is to validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients, freshly admitted at ED, with a suspected or confirmed infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Infection

Currently open trials in the same condition.

NCT07358117 — Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome · active not recruiting
NCT07110636 — Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients · NA · recruiting
NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
NCT07370948 — Study of the Antibiotic-resistance Profile of Enterobacterales Isolated From Rectal Mucosal Buffer of PrEP Subjects · recruiting

Other BioMérieux trials

Trials by the same sponsor.

NCT06449183 — VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI) · NA · completed
NCT06037109 — VIDAS® NEPHROCLEAR Reference Interval Study · completed
NCT06036758 — VIDAS® NEPHROCLEAR Diagnostic Accuracy Study · completed
NCT06257810 — Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic · NA · completed
NCT05271617 — VIDAS Nephroclear (NCL) CCL14 - Sample Stability · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04261621 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioMérieux
Last refreshed: 1 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04261621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing